What is the official ID of this bill?

The official print number for this legislation is HR 6465.

When did the legislative process begin?

The process officially started on 2023-11-21.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/hr6465/BILLS-118hr6465ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Who is the primary sponsor?

The primary sponsor is Rep. Hudson, Richard [R-NC-9].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Analysis and Potential Impact of HR 6465

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Easier Access to Plasma-Derived Medicines: New Discount Rules for Patients.

Q: What are the main provisions?

Key points include: Plasma-derived products (derived from human whole blood or plasma) will be subject to new discount rules. Different discount levels will be introduced based on whether a patient has exceeded their annual out-of-pocket drug threshold. The changes aim to reduce drug costs for patients enrolled in Medicare Part D.

This act introduces a phase-in for discounts on plasma-derived products under the manufacturer discount program. This aims to ensure better access to these specialized medicines for patients, especially for those who have incurred high treatment costs.

Key points

Plasma-derived products (derived from human whole blood or plasma) will be subject to new discount rules.

Different discount levels will be introduced based on whether a patient has exceeded their annual out-of-pocket drug threshold.

The changes aim to reduce drug costs for patients enrolled in Medicare Part D.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

PLASMA Act

Print number: HR 6465

Sponsor: Rep. Hudson, Richard [R-NC-9]

Process start date: 2023-11-21

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Easier Access to Plasma-Derived Medicines: New Discount Rules for Patients.

Key Questions about Easier Access to Plasma-Derived Medicines: New Discount Rules for Patients.